Zhejiang Wecome Pharmaceutical announced that the company's product Xuesaitong dispersible tablets has been selected for the national centralized procurement by the Chinese Patent Medicine Procurement Alliance (first batch expansion follow-up). The sales revenue of Xuesaitong dispersible tablets in 2024 is expected to be approximately 26 million yuan, with the revenue from the 40-tablet package being around 4.8 million yuan. During the procurement period, Medical Institutions will prioritize the use of selected medicines, which will help expand product sales scale and increase market share, positively impacting the company’s future operating performance. However, the signing of the procurement agreement for Xuesaitong dispersible tablets and subsequent matters and their impact are still uncertain.